drugset / Trial / NCT04970407

A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants

NCT04970407

Phase 1 Completed 45 enrolled Ipsen
RandomizedParallel-groupTriple-blindTreatment

Summary

Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)

Timeline

Start
2021-07-06
Primary completion
2022-03-16
Completion
2022-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 16 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 40 iu Intramuscular

Indications

No indication recorded.